Wednesday, June 10, 2026

Drug profile · INN

5-fu

5-fu is a dna inhibitor.

NMPA: clinical trials
Patents linked 2
Pipeline programs 5
News articles 0
Drug details — 5-fu
Class
Route
Patents
2
Programs
5
Data quality
0.70

Quick answer

5-fu is a dna inhibitor.

Key facts

INN 5-fu
Mechanism DNA inhibitor
Target DNA

Mechanism of action

DNA inhibitor

Primary target: DNA

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. 5-Fluoruracil Phase 3 · HOFFMANN-LA ROCHE · Gastric Cancer
  2. DANTE/FLOT8 Phase 3 · George Institute for · locally advanced resectable adenocarcinoma of the oesophagog
  3. 5-Fluorouracil (5-FU) Phase 2 · HALOZYME THERAPEUTICS · Gastric Adenocarcinoma or Gastroesophageal Junction Adenocar
  4. BAX69 + infusional 5-FU/LV Phase 2 · Takeda · Metastatic Colorectal Cancer
  5. ELVN-002-003 Phase 2 · Enliven Therapeutics · Solid Tumors, Colorectal Cancer and Breast Cancer

Related & competitor drugs

  1. acyclovir Human herpesvirus 1 DNA polymerase inhibitor
  2. acyclovir sodium Human herpesvirus 1 DNA polymerase inhibitor
  3. azacitidine Antineoplastic and immunomodulating agents (L01)
  4. bleomycin sulfate DNA inhibitor
  5. busulfan Antineoplastic and immunomodulating agents (L01)
  6. capecitabine Antineoplastic and immunomodulating agents (L01)

Related patents

  1. US 9868943

    Enhanced staphylolytic activity of the Staphylococcus aureus bacteriophage vB—SauS-philPLA88 virion-associated peptidoglycan hydrolase HydH5: fusions, deletions and synergy with LysH5

    Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 8986695

    Enhanced staphylolytic activity of the Staphylococcus aureus bacteriophage vB—SauS-philPLA88 virion-associated peptidoglycan hydrolase HydH5: fusions, deletions and synergy with LysH5

    Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is 5-fu?

5-fu is a dna inhibitor.